Skip to main content
Premium Trial:

Request an Annual Quote

Caliper Renews Agreement with Agilent for Microfluidic Chips

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Caliper Life Sciences today announced it has renewed its microfluidic chip supply agreement with Agilent Technologies.

Under a new seven-year agreement, Caliper will remain the exclusive supplier of microfluidic chips to Agilent for use on its Bioanalyzer 2100 platforms. Since its launch in 1999, more than 7,000 Bioanalyzer 2100 instruments have been sold, and Caliper has supplied about 5 million chips for use on the platform, Caliper said in a statement.

Agilent is Caliper's largest original equipment manufacturer customer and accounted for about 15 percent of Caliper's total microfluidic sales in 2009, Kevin Hrusovsky, president and CEO of Caliper said. In 2010 the business is expected to increase between 10 and 15 percent, "and the renewal of this relationship with its improved economics is a vital element of our strategy for sustainable double-digit growth in our microfluidics franchise over the long term," he said.

"We believe that our microfluidics technologies will continue growing as a critical tool for sample analysis as well as for sample preparation, particularly as sequencing and gene expression workflows become fundamental to the realization of personalized medicine," he added.

Financial terms of the agreement were not disclosed.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.